Gapping Down INHX -57% (Veronate failed to meet primary endpoint),
COR -47% (announces clinical hold on Ampakine CX717),
INCY -23% (to discontinue development of DFC as treatment for HIV),
RDCM -13.6% (guides Q1 revs lower), RDWR -8.5% (lowers Q1 guidance),
PGIC -8.5% (reports Q4, guides FY below consensus), GTE -7.6% (reports Q4),
MEDX -4.6% (announces 10 mln share offering), LVLT -4.4% (mentioned negatively in The Trader - Barron's),
CTHR -3.1%, NXXI -2.8%,
SNDK -2% (Goldman downgrades to Underperform),
AMD -1.7% (hearing broker downgrade),
THI -1.1%.